- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07692321
Co-designing Enhanced Models of Care for First Nations Children at Risk for Childhood-onset Type 2 Diabetes
Co-designing Enhanced Models of Care for First Nations Children at Risk for Childhood-onset Type 2 Diabetes: The Next Generation Birth Cohort.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Brandy A Wicklow, MD, MSc
- Numéro de téléphone: 204-787-1222
- E-mail: bwicklow@hsc.mb.ca
Sauvegarde des contacts de l'étude
- Nom: Elizabeth AC Sellers, MD, MSc
- Numéro de téléphone: 204-787-3011
- E-mail: esellers@hsc.mb.ca
Lieux d'étude
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 3P4
- Children's Hospital Research Institute of Manitoba/University of Manitoba
-
Contact:
- Brandy A Wicklow, MD, MSc
- Numéro de téléphone: 204781222
- E-mail: bwicklow@hsc.mb.ca
-
Contact:
- Research Coordinator
- Numéro de téléphone: 2042723064
- E-mail: NextGenStudy@chrim.ca
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria for the breastfeeding program:
- Pregnant women with type 2 diabetes or no diabetes.
- From self-identified Indigenous heritage (e.g., Cree, Oji-Cree, Métis, Anishinaabe, etc.) residing in the four Anisininew communities in the Island Lake region.
- Are delivering in Manitoba.
- Mother/Father and children must be biological family members.
Exclusion Criteria from the breastfeeding program:
- Parents or children with type 1 diabetes.
- Residing outside of Manitoba.
Inclusion criteria for the CGM pro
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Co-develop and implement a community-based perinatal education and support program using navigators
The implementation of a community-based navigator to facilitate multiple points of pre and post-partum contact as well as individualized connection to preexisting and co-developed urban and northern pre- and post-natal supports, will increase rates of initiation and duration (≥6 month) of breastfeeding in the NextGen mothers from 58% to ≥75%.
|
Co-develop and implement a community-based perinatal education and support program using navigators to support breast feeding, maternal nutrition and activity, and early infancy/childhood nutrition and activity.
|
|
Extend the scope of the NextGen Cohort
Community based point of care HbA1c testing will improve access to annual screening for pre-diabetes and diabetes in the Next Gen Cohort.
CGM can detect early dysglycemia (below the threshold for the diagnosis of prediabetes) in young children at high risk for childhood-onset T2D.
In addition, we hypothesize that CGM use will be well tolerated and feasible in young children.
|
This will allow study participants to conduct earlier and more frequent screening for early dysglycemia, prediabetes and T2D.
We will investigate the use of continuous glucose monitoring (CGM) to detect early dysglycemia in the Next Gen cohort.
|
|
Co-develop and implement community led land-based programming for parent(s) and preschool children
Land-based community programming for caregivers and children aged 4-5 years is feasible and will encourage healthy nutrition choices and physical activity.
Ultimately, we hypothesize that this will improve the health and well-being of this high-risk population and improve cardiometabolic health.
|
Co-develop and implement community led land-based programming for parent(s) and preschool children aged 4-5 years to encourage traditional nutrition and activities to maintain wellness.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of mothers who initiate breastfeeding
Délai: 3 years
|
This will be for for both groups experiencing and not experiencing diabetes during the pregnancy, exclusivity of breastfeeding and breastfeeding continuation at 1, 3 and 6 months.
In addition, we will examine the growth trajectories of infants who are breastfed and compare them to infants who are not breastfed (from historical NextGen Cohort follow up and the current project).
|
3 years
|
|
Number of eligible children in the NextGen Cohort screened per community
Délai: 3 years
|
This is a feasibility pilot to determine if participants will be screened more frequently once there are point of care HbA1C machines in each community. Qualitative data on the feasibility and implementation of the screening program via interviews with the community health care workers and NextGen families to determine facilitators and barriers to screening in community and areas of improvement for the program. |
3 years
|
|
Percentage of sensor time with glucose > 7.8 mmol/L
Délai: 3 years
|
This is to determine the feasibility of using CGM with 6 and 7 year old children.
SD of sensor glucose levels (a summary measure of glycemic variability - amplitude, frequency and duration of fluctuation in glucose measurement) and 2. tolerability and feasibility of CGM use in this population.
|
3 years
|
|
Number of times the land-based wellness program ran
Délai: 3 years
|
Feasibility of establishing and implementing this program will be assessed by metrics including how often the program ran (bench marked against number of sessions planned), and number of children participating (benchmarked against number eligible).
|
3 years
|
|
Number of children who attend the land-based wellness programming
Délai: 3 years
|
3 years
|
|
|
Number of young adult leaders hired for the land-based wellness program
Délai: 3 years
|
We anticipate that another key outcome will be capacity building for young adult leaders who will work alongside Elders and develop skills in leadership, youth health and wellness, program evaluation, and land-based curriculum development
|
3 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of mothers who enroll and participate in the breastfeeding navigator-based program
Délai: 3 years
|
3 years
|
|
|
Number classes attended by mothers who participate in the breastfeeding navigator-based program
Délai: 3 years
|
3 years
|
|
|
Qualitative review of the land-based wellness program
Délai: 3 years
|
Barriers and facilitators of program success will be co-determined by Anisininew leaders through the evaluative process, and may include qualitative interviews with family participants and leaders and/or sharing circles lead by Elders and Knowledge keepers.
|
3 years
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Brandy A Wicklow, MD, MSc, University of Manitoba, Children's Hospital Research Institute of Manitoba
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies du système endocrinien
- Maladies urogénitales féminines et complications de la grossesse
- Maladies métaboliques
- Complications de grossesse
- Troubles du métabolisme du glucose
- Diabète sucré
- Maladies nutritionnelles et métaboliques
- Diabète gestationnel
- Diabète sucré, Type 2
- Techniques d'investigation
- Thérapeutique
- Techniques de laboratoire clinique
- Techniques et procédures de diagnostic
- Diagnostic
- Soins aux patients
- Services de santé
- Conseils de soins de santé
- Phénomènes physiologiques de la reproduction
- Phénomènes physiologiques reproducteurs et urinaires
- Analyse chimique du sang
- Tests de chimie clinique
- Techniques de diagnostic, endocrine
- Surveillance, physiologique
- Période Postpartum
- Soins palliatifs
- Surveillance continue du glucose
- Lactation
Autres numéros d'identification d'étude
- 5308
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .